Anticancer virotherapy using mutant oncolytic HSV1 vectors regulated multiple pancreatic cancer associated promoters.
| Project/Area Number |
22700917
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
FUKUDA Emi 広島大学, 自然科学研究支援開発センター, 研究員 (20403503)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 癌 / ウイルス / ゲノム |
|---|
| Research Abstract |
We combined the minimal promoter region of tumor specific markers(hTERT, CEA, Survivin, ERBB2 and DF3) overexpress in the pancreatic tumor and obtained six constructs those have over 20-fold-higher promoter activity than those of full length promoters. These promoter constructs were integrated to Flip-Flop HSV BAC system and generated the recombinant herpes simplex virus. These recombinant viruses were deficient in the potential of cytotoxic activity and were not sufficient level for medical treatment.
|
Report
(3 results)
Research Products
(1 results)
